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Abstract
Background: Traumatic brain injury (TBI) is a devastating neurological condition and a frequent cause of
permanent disability. Posttraumatic inflammation and brain edema formation, two pathological key events
contributing to secondary brain injury, are mediated by the contact-kinin system. Activation of this pathway in
the plasma is triggered by activated factor XII. Hence, we set out to study in detail the influence of activated factor
XII on the abovementioned pathophysiological features of TBI.
Methods: Using a cortical cryogenic lesion model in mice, we investigated the impact of genetic deficiency of
factor XII and inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused
Infestin-4 on the release of bradykinin, the brain lesion size, and contact-kinin system-dependent pathological
events. We determined protein levels of bradykinin, intracellular adhesion molecule-1, CC-chemokine ligand 2,
and interleukin-1β by enzyme-linked immunosorbent assays and mRNA levels of genes related to inflammation by
quantitative real-time PCR. Brain lesion size was determined by tetrazolium chloride staining. Furthermore, protein
levels of the tight junction protein occludin, integrity of the blood-brain barrier, and brain water content were
assessed by Western blot analysis, extravasated Evans Blue dye, and the wet weight-dry weight method,
respectively. Infiltration of neutrophils and microglia/activated macrophages into the injured brain lesions was
quantified by immunohistological stainings.
Results: We show that both genetic deficiency of factor XII and inhibition of activated factor XII in mice diminish
brain injury-induced bradykinin release by the contact-kinin system and minimize brain lesion size, blood-brain
barrier leakage, brain edema formation, and inflammation in our brain injury model.
Conclusions: Stimulation of bradykinin release by activated factor XII probably plays a prominent role in expanding
secondary brain damage by promoting brain edema formation and inflammation. Pharmacological blocking of
activated factor XII could be a useful therapeutic principle in the treatment of TBI-associated pathologic processes
by alleviating posttraumatic inflammation and brain edema formation.
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Background
Kinins are the key regulators of vascular permeability,
edema formation, transendothelial cell migration, and
inflammation after injury in different organs [1–3]. Acti-
vation of the contact-kinin system plays a detrimental
role in traumatic brain injury (TBI), and its inhibition
has therapeutic potential [4–10]. However, translation
into clinical practice in TBI has failed thus far as it re-
mains unclear which component of this system is best
suited as a therapeutic target structure [3].
Coagulation factor XII (FXII; Hageman factor) plays a
leading role in injury-induced thrombosis and inflamma-
tion [11]. Activation of FXII (generating activated FXII
(FXIIa)) via contact with negatively charged surfaces or
inorganic polyphosphates released from activated plate-
lets not only triggers the intrinsic coagulation cascade
but also cleaves plasma prekallikrein to form plasma kal-
likrein. Plasma kallikrein in turn induces the release of
bradykinin from high molecular weight kininogen (for
review, see [2, 11]. Plasma kallikrein can further activate
FXII via a positive feedback loop [11]. As deficiency of
FXII in patients is not associated with a bleeding pheno-
type, the contact pathway was originally thought to be
dispensable for physiological hemostasis [11]. The gener-
ation of FXII knockout mice challenged this dogma as
those mice exhibit severely impaired thrombus forma-
tion [12]. We recently reported that both the genetic de-
ficiency of FXII and the pharmacologic inhibition of
FXIIa prevented thrombus formation, neurodegenera-
tion, and functional deficits after brain trauma without
increasing bleeding risk, pointing to a novel treatment
option [13]. Hence, we set out to study in detail the in-
fluence of FXIIa inhibition on inflammation and brain
edema formation, two pathological key events that are
mediated by the contact-kinin pathway after brain
injuries [4, 13]. We used the cryolesion model that is
particularly suited to mimic posttraumatic inflammation
and brain edema formation in an extremely well-
standardized and reliable fashion but lacks the contre-
coup and diffuses axonal injuries that often complicate
human head injuries [14]. Our results show that inhib-
ition of FXIIa diminishes brain injury-induced bradyki-
nin release and reduces lesion size, edema formation,
blood-brain barrier damage, and inflammation.
Methods
Animals
A total of 243 male C57Bl/6N (wildtype) mice and 55
male FXII-deficient (FXII−/−) mice [15] at the age of
6 weeks were used in this study. Mice were housed
in groups of three to eight with free access to food
and water and a 12-h light/12-h dark cycle. In this
study, all experiments were approved by institutional
and regulatory authorities and were conducted in
accordance with the EU Directive 2010/63/EU and
the ARRIVE criteria [16].
Cortical cryolesion model
Cortical cryolesion was induced as described previously
[14]. Briefly, the mice were anesthetized with an intra-
peritoneal injection of ketamine (0.1 mg/g body weight)
and xylazine (0.005 mg/g body weight). After restraining
the mouse head in a stereotactic frame, surgery was per-
formed on the right parietal cortex after exposing the
skull through a scalp incision. A copper cylinder with a
tip diameter of 2.5 mm was filled with liquid nitrogen
(−196 °C) and placed on the right parietal cortex (coor-
dinates from the bregma 1.5 mm caudal, 1.5 mm lateral)
for 90 s. Sham-operated animals underwent the same
surgical procedure without cooling of the copper cylin-
der. All surgical procedures were performed by the same
person, and animals were randomly assigned to the dif-
ferent treatment groups.
Pharmacological treatment
One hour after induction of focal cryolesion, a group of
74 wildtype mice received a single intravenous injection
of the specific FXIIa inhibitor rHA-Infestin-4 (CSL
Behring GmbH, Marburg, Germany) at a dose of
200 mg/kg body weight [13]. Control animals received
equal volumes of 0.9% sodium chloride (vehicle).
Determination of lesion size after cortical cryolesion
Mice were sacrificed 2 h, 1 day (1d), or 3 days (3d) after
cryolesion; the brains were quickly removed and cut in
five 1-mm-thick coronal sections using a mouse brain
slice matrix (Harvard Apparatus). The slices were
stained for 10 min at room temperature with 2% 2,3,5-
triphenyltetrazolium chloride (TTC; Sigma-Aldrich) in
1× phosphate-buffered saline (PBS) to visualize the le-
sion. The lesion volume was calculated from the TTC-
stained slices using the ImageJ software (Open Source,
National Institutes of Health, USA).
Determination of brain edema and blood-brain barrier
leakage
Brain edema formation was calculated using the wet
weight-dry weight method. Briefly, 1d after cryolesion,
the brains were quickly removed and 8-mm-thick cor-
onal sections from the injured (ipsilateral) and non-
injured (contralateral) brain hemispheres were sampled.
The freshly collected tissue samples were weighted to as-
sess the wet weight. To assess the dry weight, samples
were dried for 24 h at 50 °C and then weighted again.
The water content (expressed as percentage) in the ipsi-
lateral and contralateral brain hemisphere was calculated
using the following formula:
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wet weight – dry weightð Þ = wet weightð Þ  100
To determine blood-brain barrier leakage, extravasa-
tion of Evans Blue tracer into the brain parenchyma was
measured fluorometrically as described previously [17].
The mice received 100 μl of 2% Evans Blue solved in
0.9% NaCl 4 h before they were sacrificed. The brains
were quickly removed and 8-mm-thick coronal sections
from the ipsilateral and contralateral brain hemispheres
were sampled. The tissue samples were post-fixed in 4%
paraformaldehyde (PFA). After fixation, the tissue
samples were incubated for 24 h in 500 μl formamide at
50 °C in the dark to extract the Evans Blue dye. Then,
the tissue samples were centrifuged and the fluorescence
intensity of the supernatant was measured in duplicates
by a fluorometer (Fluoroskan Ascent, Thermo Scientific)
at an excitation wavelength of 610 nm and an emission
wavelength of 680 nm. The concentration for each sam-
ple was calculated from a standard curve.
Gene expression analysis
Real-time PCR was used to determine relative gene ex-
pression levels of genes related to inflammation in the
ipsilateral cortices. Tissue homogenization, RNA isola-
tion, and real-time PCR were performed as previously
described [5]. Total RNA was prepared with a Polytron
PT2100 homogenizer (Kinematica, Luzern, Switzerland)
using the TRIzol Reagent (Invitrogen, Karlsruhe,
Germany). Then, 250 μg of total RNA was reversely
transcribed with the TaqMan Reverse Transcription
Reagents (Applied Biosystems, Darmstadt, Germany)
according to manufacturer’s protocol using random
hexamers. Relative gene expression levels of interleukin
(IL)-1β (assay ID Mm00434228_m1, Applied Biosys-
tems), tumor necrosis factor (TNF) α (assay ID
Mm00443258_m1, Applied Biosystems), CC-chemokine
ligand (CCL) 2 (assay ID Mm00441242_m1, Applied
Biosystems), and intracellular adhesion molecule
(ICAM)-1 (assay ID Mm00516023_m1, Applied Biosys-
tems) were quantified with the fluorescent TaqMan®
technology. GAPDH and β-actin (TaqMan® Predeve-
loped Assay Reagents for gene expression, part numbers
4352339E and 4352341E; Applied Biosystems) were used
as endogenous controls to normalize the amount of
sample RNA. The real-time PCR was performed with
equal amounts of cDNA in the 7500 Real-Time PCR
System (Applied Biosystems) using the TaqMan®
Universal 2× PCR Master Mix (Applied Biosystems). Re-
actions (total volume 12.5 μl) were incubated at 50 °C for
2 min, at 95 °C for 10 min followed by 40 cycles of 15 s at
95 °C, and 1 min at 60 °C. Water controls were included
to ensure specificity. The 2−ΔΔCt method was used for the
relative quantification of gene expression [18].
Western blot analysis
Immunoreactivity for occludin (anti-occludin, ab31721,
1:5,000, Abcam) in the lesioned cortices was detected by
Western blot analysis as previously described [4]. Densi-
tometric analysis of occludin was performed in a blinded
fashion using ImageJ software with β-actin (A5441,
1:500,000, Dianova) as loading control to normalize the
levels of occludin detected.
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [4]. The cryo-embedded mouse brains were cut
into 10-μm-thick slices using a cryostat (Leica). The
slices were fixed in 4% PFA in PBS for 15 min. Blocking
of epitopes was achieved by pre-treatment with 5%
bovine serum albumin (BSA) in PBS for 60 min to
prevent unspecific binding. For the detection of
macrophages/activated microglia, an anti-CD11b anti-
body (1:100; MCA711, AbD Serotec) and, for the detec-
tion of neutrophils, an anti-Ly-6B.2 antibody (1:100;
MCA771GA, AbD Serotec) were applied. Afterwards,
slides were incubated with a biotinylated anti-rat IgG
(1:100; BA-4001, Vector Laboratories) in PBS containing
1% BSA overnight at 4 °C. Following the incubation with
an avidin/biotin complex (Vectastain® ABC Kit, Biozol
Diagnostica) for 60 min, the immune cells were visual-
ized via addition of diaminobenzidine (Peroxidase Sub-
strate Kit DAB SK-4100, Vector Laboratories). The slices
were embedded in AquaTex (Merck). Cell numbers were
counted at a 40-fold magnification in the ipsilateral
hemispheres of five brain slices under a Nikon micro-
scope Eclipse 50i equipped with the DS-U3 DS camera
control unit and the NIS-Elements software (Nikon). For
quantitative analysis, we used sections from near-
identical brain regions for better comparison between
groups. Negative controls for all immunohistological ex-
periments included omission of either the primary or
secondary antibody and gave no signals (not shown). For
taking representative images, we used an Axioplan 2
Zeiss microscope equipped with a Visitron Systems Spot
Insight 4 M Pixel color camera and the Spot Imaging 5.2
software (Diagnostic Instruments, Inc.).
Enzyme-linked immunosorbent assays
For measurement of protein concentrations in plasma,
whole blood was sampled in heparinized tubes. After re-
moving the cells by centrifuging in a refrigerated centri-
fuge, the resulting supernatant (plasma) was used for
enzyme-linked immunosorbent assays (ELISA) to meas-
ure bradykinin levels. To measure ICAM-1 levels in the
plasma, a 50-fold dilution was required. To determine
the levels of CCL2 and IL-1β, the ipsilateral brain
hemispheres were quickly removed and homogenized
(Sonopuls HD60 ultrasonic homogenizer, Bandelin,
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Berlin, Germany) using an extraction buffer (20 mM
Tris, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 1%
TritonX-100) supplemented with complete protease in-
hibitor cocktail tablet (Roche Diagnostics) (1 ml/100 mg
brain tissue). All ELISA were performed in duplicate
according to manufacturer’s instructions (bradykinin
ELISA: Bradykinin Fluorescent EIA Kit, FEK-009-01,
Phoenix Pharmaceuticals; ICAM-1 ELISA: Mouse ICAM-
1/CD54 Quantikine ELISA Kit, MIC100, R&D Systems;
CCL2 ELISA: Mouse/Rat CCL2/JE/MCP-1 Quantikine
ELISA Kit, MJE00, R&D Systems; IL-1β ELISA: Mouse IL-
1 beta/IL-1F2 Quantikine ELISA Kit, MLB00C, R&D Sys-
tems). The fluorescent products for bradykinin ELISA
were read at a fluorometer (Fluoroskan Ascent, Thermo
Scientific) with wavelengths of 355 nm (excitation) and
460 nm (emission). All other assays were read at 450 nm
at a photometer (MultiskanEX, Thermo Scientific).
Statistics
The numbers of animals necessary to detect a standard-
ized effect size on lesion volumes ≥0.2 on day 1 after
Table 1 Determination of bradykinin plasma level by ELISA 2 h
after injury induction reveals a reduction of bradykinin in FXII−/−
mice and animals treated with rHA-Infestin-4 similar to uninjured
animals (Sham) when compared with injured wildtype (WT)
and vehicle-treated mice (Vehicle) (n = 5 per group, **P < 0.01,
*P < 0.05, one-way ANOVA followed with Bonferroni multiple
comparison test and unpaired, two-tailed Student’s t test,
respectively)















*P < 0.05 WT vs FXII−/−; #P < 0.05 Vehicle vs rHA-Infestin-4
Fig. 1 Genetic deficiency and pharmacologic inhibition of factor XIIa
provides protection from tissue damage. Lesion volumetry shows
less necrotic brain tissue in FXII−/− mice and mice treated with
rHA-Infestin-4 in comparison with control groups after 1 day (d1)
and 3 days (d3), respectively (n = 8, **P < 0.01, *P < 0.05, unpaired,




Fig. 2 Factor XII (FXII) deficiency and pharmacologic inhibition of
activated FXII displays blood-brain barrier stabilizing and antiedematous
effects 1 and 3 days after induction of focal trauma. a Fluorometric
measurement of Evans Blue extravasation into the brain parenchyma
after 2 h, 12 h, 1 day (d1), and 3 days (d3) in mice treated with
rHA-Infestin-4 or vehicle (n = 5–6 per group, *P < 0.05, unpaired,
two-tailed Student’s t test). b Fluorometric measurement of Evans
Blue extravasation into the brain parenchyma after 1 (d1) and
3 days (d3) in wildtype (WT) mice and FXII-deficient (FXII−/−) mice
(n= 5–6 per group, ***P < 0.001, *P< 0.05, unpaired, two-tailed Student’s
t test). Right panel shows representative brain slices of Evans Blue
extravasation into the tissue. c Antiedematous effect in FXII deficiency
and FXIIa inhibition shown by determination of brain water content in
the lesioned hemisphere 24 h after trauma (n = 8–9, *P < 0.05,
unpaired, two-tailed Student’s t test)
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cortical cryolesion were determined via a priori sample
size calculation with the following assumptions: α = 0.05,
β = 0.2, mean, and standard deviation (G*Power 3.0.10).
Mice were randomly assigned to treatment groups (block
randomization after cryolesion). To avoid bias, experi-
ments were performed and analyzed in a blinded fashion.
All results were expressed as mean ± SEM. For statis-
tical analysis, PrismGraph 5.0 software package (Graph-
Pad Software, GraphPad Inc., La Jolla, CA, USA) was
used. Data were tested for Gaussian distribution with
the Kolmogorov–Smirnov test and, in the case of meas-
uring the effects of two factors simultaneously, analyzed
by two-way ANOVA with post hoc Bonferroni correc-
tion for multivariate analysis. In the case of measuring
the effect of one factor, one-way ANOVA with post hoc
Bonferroni correction was applied. If only two groups
were compared, unpaired, two-tailed Student’s t test was
performed. P values <0.05 were considered statistically
significant.
Results
Factor XII promotes bradykinin release after focal brain
injury
Within 2 h, focal brain injury results in increased plasma
bradykinin levels in wildtype and vehicle-treated mice
when compared to FXII-deficient or rHA-Infestin-4-
treated mice, respectively (Table 1). Accordingly, we ob-
served diminished lesion sizes in FXII-deficient mice
and rHA-Infestin-treated mice 1d and 3d after focal le-
sion when compared to control mice (wildtype mice and
vehicle-treated mice, respectively) (Fig. 1).
Brain edema formation and blood-brain barrier breakdown
are dependent on factor XII
Bradykinin levels in patients with TBI correlate with the
extent of edema evolution [19]. Thus, we next sought to
investigate the impact of FXII on brain edema formation
and blood-brain barrier function.
The integrity of the blood-brain barrier, as reflected by
the concentration of the vascular tracer Evans Blue
leaking into the brain parenchyma, was comparable in
rHA-Infestin-4-treated mice and control mice at early
time points (2 and 12 h post-injury) but was preserved
in rHA-Infestin-4-treated mice 1d and 3d after focal
brain injury when compared to their vehicle controls
(Fig. 2a). Also in FXII-deficient mice less Evans Blue
leaked into the brain parenchyma 1d and 3d after focal
brain injury when compared to their respective control
groups (Fig. 2b). Brain edema formation as assessed by
the wet weight-dry weight method was significantly
Fig. 3 Factor XII (FXII)-deficiency and pharmacologic inhibition of activated FXII inhibits degradation of tight junction protein occludin.
Quantification of occludin by Western blot analysis on day 1 (d1, upper panel) and on day 3 (d3, lower panel) after injury in sham-operated animals,
WT mice and FXII−/− mice (left), and sham-operated mice and mice treated with rHA-Infestin-4 or vehicle (right), respectively (n = 5 per group, **P
< 0.01, *P < 0.05, one-way ANOVA followed by Bonferroni multiple comparison test compared with WT mice, AU arbitrary units)
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reduced in FXII-deficient mice and in mice treated
with rHA-Infestin-4 (Fig. 2c). We also found higher
levels of the tight junction protein occludin in FXII-
deficient and rHA-Infestin-4-treated mice compared
to control mice (Fig. 3).
Inflammatory processes are promoted by factor XII
Bradykinin also promotes inflammatory processes, such
as immune cell migration from the vasculature to sites
of inflammation (for comprehensive review, see [20]). A




Fig. 4 Factor XII enhances inflammatory processes after traumatic brain injury. a Determination of CCL2 protein concentrations in the brain tissue
of sham-operated mice and mice treated with rHA-Infestin-4 or vehicle 2, 6, and 12 h, and 1 day (d1) after injury (n = 4–5 per group, ***P < 0.001,
one-way ANOVA followed by Bonferroni multiple comparison test). b Quantification of CCL2 concentrations in the brain tissue of FXII−/− mice,
sham-operated mice, and wildtype controls 12 h and 1 day (d1) after injury (n = 4–5 per group, ***P < 0.001, **P < 0.01, *P < 0.05, one-way ANOVA
followed by Bonferroni multiple comparison test compared with WT mice)−/−. c Relative gene expression of CCL2 in the injured cortices of
FXII-deficient mice and wildtype controls, and rHA-Infestin-4- and vehicle-treated mice on day 1 after trauma induction (n = 5 per group, *P < 0.05,
unpaired, two-tailed Student’s t test, amount of gene expression normalized to sham-operated animals (not shown)). d Macrophages and activated
microglia were quantified in the lesioned hemispheres after 1 (d1) and 3 days (d3) after brain trauma (left). Representative immunohistochemical
stainings of CD11b-positive macrophages/microglia in FXII-deficient animals and wildtype mice on d1 (right). Scale bar depicts 100 μm (n = 4,
***P < 0.001, **P < 0.01, *P < 0.05, unpaired, two-tailed Student’s t test)
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site of tissue injury is CCL2 (monocyte chemoattractant
protein 1, MCP-1). We therefore analyzed the time
course of CCL2 tissue levels after focal brain injury. At 2
and 6 h, the levels of CCL2 in brain-injured mice
remained at the same levels as in sham-treated mice.
Subsequently, at 12 h and 1d, CCL2 levels were in-
creased in vehicle-treated mice but remained on sham
levels in rHA-Infestin-4-treated mice (Fig. 4a). Similarly,
at 12 h and 1d, CCL2 levels were increased in wildtype
mice but remained on sham levels in FXII-deficient mice
(Fig. 4b). Moreover, FXII deficiency or rHA-Infestin-4
treatment resulted in significantly diminished messenger
RNA (mRNA) expression of the CCL2-encoding genes
when compared to the respective control groups (Fig. 4c).
This was paralleled by significantly reduced migration of
macrophages/activated microglia to the site of injury.
More macrophages/activated microglial cells had en-
tered the injured brain hemispheres of untreated
wildtype mice when compared with mice that were defi-
cient for FXII or were treated with rHA-Infestin-4
(Fig. 4d). Macrophages can release various inflammatory
mediators after kinin stimulation including IL-1β and
TNF-α (for comprehensive review, see [20]). In
accordance, the protein levels of IL-1β 1d after focal
brain lesions as assessed by ELISA were lower in FXII-
deficient and rHA-Infestin-4-treated mice when com-
pared to untreated wildtype and vehicle-treated mice, re-
spectively (Fig. 5a). Significantly less mRNA of genes
encoding for IL-1β and TNF-α was present in the in-
jured cortices of rHA-Infestin-4-treated FXII-deficient
mice when compared to vehicle-treated mice 1d and 3d
after focal injury (Fig. 5b).
Next, we quantified the numbers of neutrophils in-
vading the injured brain hemispheres by immunohis-
tochemistry 1d and 3d after the induction of focal
brain lesion. We observed more neutrophils in the
injured brain hemispheres of untreated wildtype mice
when compared to FXII-deficient mice or rHA-
Infestin-4-treated mice (Fig. 6a). When we analyzed
the mRNA levels of the ICAM-1-encoding genes and
plasma protein levels of ICAM-1, which promote the
migration of neutrophils to the site of injury [21], we
found higher numbers in untreated wildtype mice
a
b
Fig. 5 a Determination of interleukin-1β (IL-1β) concentrations in
the brain tissue of sham-operated mice, FXII−/− mice, and mice
treated with rHA-Infestin-4 and their respective controls on day 1
after injury (n = 4–5 per group, ***P < 0.001, **P < 0.01, *P < 0.05,
one-way ANOVA followed by Bonferroni multiple comparison test
compared with WT mice). b Relative gene expression of IL-1β (lower
panel) and tumor necrosis factor α (TNF-α, upper panel) in the injured
cortices of rHA-Infestin-4- and vehicle-treated mice on day 1 (d1)
and day 3 (d3) after trauma induction (n = 5 per group, **P < 0.01,
*P < 0.05, unpaired, two-tailed Student’s t test, amount of gene
expression normalized to sham-operated animals (not shown))
Hopp et al. Journal of Neuroinflammation  (2017) 14:39 Page 7 of 10
when compared to FXII-deficient mice or rHA-
Infestin-4-treated mice 3d after focal brain injury
(Fig. 6b–c).
Discussion
Bradykinin as the major product of the contact-kinin
system triggers inflammation and brain edema formation
(for a comprehensive overview, see [2]). In this study, we
aimed at targeting FXIIa, the very first step required for
activation of this pathway in the plasma to alleviate
pathological events leading to secondary injury after
brain trauma.
Following brain trauma, bradykinin levels in the cere-
brospinal fluid of patients are markedly elevated up to
48 h and decrease thereafter, reaching levels of the con-
trol group within 72 h after injury [19]. Similar to the
human situation, bradykinin levels maximally increase
within 2 h in the brain tissue of mice after experimen-
tally induced focal brain trauma and then subsequently
decline [7]. In accordance, we observed that plasma
bradykinin levels increased twofold to threefold within
2 h after focal cortical injury in mice. As FXIIa activates
plasma kallikrein, it is plausible to assume that posttrau-
matic bradykinin release is dependent on the availability
of FXIIa. Plasma bradykinin levels were significantly
lower in mice deficient for FXII or treated with the spe-
cific FXIIa inhibitor rHA-Infestin-4.
Bradykinin levels in the cerebrospinal fluid of patients
with brain trauma correlate with the extent of brain
edema formation [19]. There is profound experimental
evidence that activation of the contact-kinin system fol-
lowing brain trauma destabilizes the blood-brain barrier
and leads to vasogenic brain edema [6–8, 22], most
probably via bradykinin release [7]. Our results also
point to bradykinin being critically involved in blood-
brain barrier instability and brain edema formation after
brain trauma. The extent of blood-brain barrier leakage
and brain edema in the present study was significantly
less severe in FXII-deficient mice or mice treated with
rHA-Infestin-4 when compared to untreated wildtype
mice.
Bradykinin is known to advance inflammation after
CNS injury [23]. The inflammatory processes in turn
promote posttraumatic neuronal cell loss [24–26]. In
agreement with the present study, we reported earlier
that blocking bradykinin receptor 1 [6] or bradykinin re-
lease by a C1 inhibitor [4] reduced invasion of macro-
phages and activated microglia into the damaged brain
a
b c
Fig. 6 Factor XII enhances inflammatory processes after traumatic brain injury. a Neutrophils were quantified in the lesioned hemispheres after 1
(d1) and 3 days (d3) after brain trauma (left). Representative immunohistochemical stainings of neutrophils in FXII-deficient animals and wildtype
mice on d1 (right). Scale bar depicts 50 μm (n = 4, **P < 0.01, *P < 0.05, unpaired, two-tailed Student’s t test). b Determination of ICAM-1 plasma
concentrations of sham-operated mice, FXII−/− mice and mice treated with rHA-Infestin-4 and their respective controls on day 3 after injury (n =
4–5 per group, *P < 0.05, one-way ANOVA followed by Bonferroni multiple comparison test compared with WT mice). c Relative gene expression
of ICAM-1 in FXII-deficient mice (left) and rHA-Infestin-4-treated mice (right) in comparison to their respective control groups 3 days after trauma
induction (n = 5, ***P < 0.001, **P < 0.01, unpaired, two-tailed Student’s t test, amount of gene expression normalized to sham-operated animals
(not shown))
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tissue and suppressed the gene expression of IL-1β and
TNF-α 24 h after cortical brain injury in mice. In the
current study using FXII-deficient mice or rHA-Infestin-
4 treatment, we corroborated these earlier findings and
showed sustained amelioration of the injury until day 3.
The beneficial effects on inflammatory cell invasion were
paralleled by reduced protein and mRNA levels of
CCL2, a key chemokine regulating migration and infil-
tration of monocytes/macrophages [27] into the lesioned
brain tissue. Moreover, we observed lower numbers of
neutrophils and lower levels of the cell adhesion mol-
ecule ICAM-1 in FXII-deficient mice or mice treated
with rHA-Infestin-4 until day 3 after focal brain lesion.
Our data strongly suggest that FXIIa enhances inflam-
matory processes after brain trauma via activation of the
contact-kinin pathway.
In addition to triggering bradykinin release, FXIIa also
initiates the intrinsic coagulation pathway [11]. We
showed recently that deficiency of FXII or inhibition
of FXIIa improved the outcome and impeded
thrombus formation in the brain microvasculature
after a closed head injury in mice [13]. This beneficial
effect seemed to be dependent on the activation of
the intrinsic coagulation pathway as the injury-
induced microvascular thrombosis, brain damage, and
functional deficits could be recovered in FXII-
deficient mice by the administration of hFXII but not
by the administration of a recombinant hFXII variant
that cannot be activated due to modifications in the
activation domain [13]. However, inflammatory pro-
cesses and coagulation seem to be closely intercon-
nected (reviewed in [28–30]. As an example, von
Brühl and colleagues showed that platelet-mediated
leukocyte recruitment and activation contribute to the
initiation and propagation of thrombosis [31]. In a
mouse model of deep vein thrombosis (DVT), they
revealed that platelets expressing glycoprotein Ibα
contribute to thrombus formation by supporting accu-
mulation of the innate immune cells and by binding
to leukocytes [31]. Interestingly, thrombus-resident
neutrophils are indispensable for subsequent DVT
propagation by binding FXII and thereby supporting
its activation [31]. Even if the discrete mechanisms
linking inflammation and thrombosis are insufficiently
investigated, it is likely that inflammation triggered by
FXIIa also contributes to microvascular thrombosis.
Conclusions
Taken together, we demonstrate here that bradykinin re-
lease is increased in our brain injury model and that this
increase can be blocked by inhibition of FXIIa. Stimula-
tion of bradykinin release seems to have a prominent
role in expanding secondary brain damage by promoting
brain edema formation and inflammation as all these
detrimental effects can be effectively alleviated by block-
ing FXIIa. As inhibition of FXIIa does not increase the
risk of intracranial hemorrhage [13], FXIIa is a promis-
ing target for the acute treatment of brain trauma by
inhibiting two essential signaling cascades.
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